Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: An ultrahigh-pressure acid-fracturing isodiametric hose assembly, comprising a hose body and a metal joint. The metal joint comprises an inner tube, a first outer tube the inner tube, and a second outer tube. The first outer tube and the second outer tube each is an independent pressing part. An external groove is provided at an outer wall of the inner tube. An end of the first outer tube comprises an internal ridge which matches the external groove for snapping. The terminal of the inner tube comprises a connecting portion. An outer wall of the inner tube comprises a first protrusion, and an inner wall of the first outer tube comprises a second protrusion engaging with the first protrusion. The hose body is clamped between the first protrusion and the second protrusion that are engaged. An inner wall of the second outer tube comprises multiple micro-protrusions.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: A hydrogel network includes a hydrogel polymer having a coupling site, an oligonucleotide conjugated at a terminal end to the hydrogel polymer at the coupling site, and a functional moiety coupled between the terminal end of the oligonucleotide and the coupling site. Such a hydrogel network can be formed by a method including activating a coupling site of a substrate and binding a linker moiety coupled to a terminal end of an oligonucleotide to the activated coupling site, a functional moiety coupled between the terminal end of the oligonucleotide and the linker moiety.

Abstract: A polymer substrate, such as a polymer particle, is formed from a carboxyl functional monomer. In an example, the carboxyl functional monomer has a protection group in place of the OH of the carboxyl group. Once the monomer is polymerized, such a protection group can be removed, providing a polymer network with carboxyl functional sites. Such sites can be used to attach other functionality to the polymer substrate.

Abstract: A hydrogel network includes a hydrogel polymer having a coupling site, an oligonucleotide conjugated at a terminal end to the hydrogel polymer at the coupling site, and a functional moiety coupled between the terminal end of the oligonucleotide and the coupling site. Such a hydrogel network can be formed by a method including activating a coupling site of a substrate and binding a linker moiety coupled to a terminal end of an oligonucleotide to the activated coupling site, a functional moiety coupled between the terminal end of the oligonucleotide and the linker moiety.

Abstract: A polymer substrate, such as a polymer particle, is formed from a carboxyl functional monomer. In an example, the carboxyl functional monomer has a protection group in place of the OH of the carboxyl group. Once the monomer is polymerized, such a protection group can be removed, providing a polymer network with carboxyl functional sites. Such sites can be used to attach other functionality to the polymer substrate.

Abstract: A hydrogel network includes a hydrogel polymer having a coupling site, an oligonucleotide conjugated at a terminal end to the hydrogel polymer at the coupling site, and a functional moiety coupled between the terminal end of the oligonucleotide and the coupling site. Such a hydrogel network can be formed by a method including activating a coupling site of a substrate and binding a linker moiety coupled to a terminal end of an oligonucleotide to the activated coupling site, a functional moiety coupled between the terminal end of the oligonucleotide and the linker moiety.

Abstract: A polymer substrate, such as a polymer particle, is formed from a carboxyl functional monomer. In an example, the carboxyl functional monomer has a protection group in place of the OH of the carboxyl group. Once the monomer is polymerized, such a protection group can be removed, providing a polymer network with carboxyl functional sites. Such sites can be used to attach other functionality to the polymer substrate.

Abstract: A polymer substrate, such as a polymer particle, is formed from a carboxyl functional monomer. In an example, the carboxyl functional monomer has a protection group in place of the OH of the carboxyl group. Once the monomer is polymerized, such a protection group can be removed, providing a polymer network with carboxyl functional sites. Such sites can be used to attach other functionality to the polymer substrate.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with Retinitis Pigmentosa and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: A hydrogel network includes a hydrogel polymer having a coupling site, an oligonucleotide conjugated at a terminal end to the hydrogel polymer at the coupling site, and a functional moiety coupled between the terminal end of the oligonucleotide and the coupling site. Such a hydrogel network can be formed by a method including activating a coupling site of a substrate and binding a linker moiety coupled to a terminal end of an oligonucleotide to the activated coupling site, a functional moiety coupled between the terminal end of the oligonucleotide and the linker moiety.

Abstract: A polymer substrate, such as a polymer particle, is formed from a carboxyl functional monomer. In an example, the carboxyl functional monomer has a protection group in place of the OH of the carboxyl group. Once the monomer is polymerized, such a protection group can be removed, providing a polymer network with carboxyl functional sites. Such sites can be used to attach other functionality to the polymer substrate.

Abstract: The invention provides compositions and methods for the prevention, amelioration, and/or treatment of diabetes complications, including ocular diseases associated with increased glucose transport and/or oxidative stress.

Abstract: The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding-induced eIF-5A; and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine synthase (“DHS”), polynucleotides that encode DHS, and methods involving modulating the expression of DHS.

Abstract: An engine comprises a tank of compressed air and a piston. The tank of compressed air is connected to a conduit and the conduit is connected to a cylinder comprising a first valve and an inlet to a chamber. The chamber comprises the piston, which reciprocates. The chamber also has a second outlet connected to a second valve. The air traverses from the tank of compressed into the chamber by opening the first valve. Both the first valve and second valve are closed and the compressed air moves the piston in the chamber to produce work. The second valve opens and the air escapes from the chamber and the piston.

Abstract: An engine comprises a tank of compressed air and a piston. The tank of compressed air is connected to a conduit and the conduit is connected to a cylinder comprising a first valve and an inlet to a chamber. The chamber comprises the piston, which reciprocates. The chamber also has a second outlet connected to a second valve. The air traverses from the tank of compressed into the chamber by opening the first valve. Both the first valve and second valve are closed and the compressed air moves the piston in the chamber to produce work. The second valve opens and the air escapes from the chamber and the piston.